FDA Clinical Inspection Summary: Mavyret (glecaprevir/pibrentasavir-ABT-493+ABT-530) submitted by Abbvie

FDA did not post any warning letters to Sponsors/Monitors/CROs, IRBs or Clinical Investigators this week. From the archives, here is the Clinical Inspection Summary for Mavyret (glecaprevir/pibrentasavir-ABT-493+ABT-530), submitted by Abbvie. Seven sites were inspected. Inspections ranged from three to seven days. Two sites received FDA Form 483s.

Dr. Jazrawi was cited for:

  • Inadequate documentation to support one subject met inclusion criteria for two lab values

Dr. Zogg was cited for:

  • Lack of documentation to support kit numbers dispensed and returned. (NOTE: FDA notes that the investigator stated that this function was performed by the Interactive Response Technology provider contracted by the sponsor, but FDA still issued the 483 to the site. FDA further notes that the investigator submitted an acceptable corrective action plan.)